PD-L1 expression in neuroendocrine tumors of the lung

Kenjiro Tsuruoka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Keisuke Asakura, Kazuo Nakagawa, Hiroyuki Sakurai, Shun ichi Watanabe, Koji Tsuta, Yuichiro Ohe

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalLung Cancer
Volume108
DOIs
Publication statusPublished - 2017 Jun 1
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Cell Death
Ligands
Lung
Carcinoid Tumor
Neuroendocrine Carcinoma
Large Cell Carcinoma
Small Cell Lung Carcinoma
CD274 Antigen
Neoplasms
Cancer Care Facilities
Tokyo
Histology
Japan
Clone Cells
Demography
Staining and Labeling
Antibodies
Pharmaceutical Preparations

Keywords

  • Carcinoid
  • Clone E1L3N
  • Immunohistochemistry
  • LCNEC
  • Neuroendocrine
  • PD-1
  • PD-L1
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., ... Ohe, Y. (2017). PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006

PD-L1 expression in neuroendocrine tumors of the lung. / Tsuruoka, Kenjiro; Horinouchi, Hidehito; Goto, Yasushi; Kanda, Shintaro; Fujiwara, Yutaka; Nokihara, Hiroshi; Yamamoto, Noboru; Asakura, Keisuke; Nakagawa, Kazuo; Sakurai, Hiroyuki; Watanabe, Shun ichi; Tsuta, Koji; Ohe, Yuichiro.

In: Lung Cancer, Vol. 108, 01.06.2017, p. 115-120.

Research output: Contribution to journalArticle

Tsuruoka, K, Horinouchi, H, Goto, Y, Kanda, S, Fujiwara, Y, Nokihara, H, Yamamoto, N, Asakura, K, Nakagawa, K, Sakurai, H, Watanabe, SI, Tsuta, K & Ohe, Y 2017, 'PD-L1 expression in neuroendocrine tumors of the lung', Lung Cancer, vol. 108, pp. 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006
Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2017 Jun 1;108:115-120. https://doi.org/10.1016/j.lungcan.2017.03.006
Tsuruoka, Kenjiro ; Horinouchi, Hidehito ; Goto, Yasushi ; Kanda, Shintaro ; Fujiwara, Yutaka ; Nokihara, Hiroshi ; Yamamoto, Noboru ; Asakura, Keisuke ; Nakagawa, Kazuo ; Sakurai, Hiroyuki ; Watanabe, Shun ichi ; Tsuta, Koji ; Ohe, Yuichiro. / PD-L1 expression in neuroendocrine tumors of the lung. In: Lung Cancer. 2017 ; Vol. 108. pp. 115-120.
@article{ea7e2df440a741ad93d292dbfdd3599e,
title = "PD-L1 expression in neuroendocrine tumors of the lung",
abstract = "Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100{\%}]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4{\%})/4 (5.8{\%}). Conclusions PD-L1 expression was apparent in 10.4{\%} of LCNEC and 5.8{\%} of SCLC tumors, and was not observed in carcinoid tumors.",
keywords = "Carcinoid, Clone E1L3N, Immunohistochemistry, LCNEC, Neuroendocrine, PD-1, PD-L1, Small cell lung cancer",
author = "Kenjiro Tsuruoka and Hidehito Horinouchi and Yasushi Goto and Shintaro Kanda and Yutaka Fujiwara and Hiroshi Nokihara and Noboru Yamamoto and Keisuke Asakura and Kazuo Nakagawa and Hiroyuki Sakurai and Watanabe, {Shun ichi} and Koji Tsuta and Yuichiro Ohe",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2017.03.006",
language = "English",
volume = "108",
pages = "115--120",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - PD-L1 expression in neuroendocrine tumors of the lung

AU - Tsuruoka, Kenjiro

AU - Horinouchi, Hidehito

AU - Goto, Yasushi

AU - Kanda, Shintaro

AU - Fujiwara, Yutaka

AU - Nokihara, Hiroshi

AU - Yamamoto, Noboru

AU - Asakura, Keisuke

AU - Nakagawa, Kazuo

AU - Sakurai, Hiroyuki

AU - Watanabe, Shun ichi

AU - Tsuta, Koji

AU - Ohe, Yuichiro

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

AB - Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.

KW - Carcinoid

KW - Clone E1L3N

KW - Immunohistochemistry

KW - LCNEC

KW - Neuroendocrine

KW - PD-1

KW - PD-L1

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85016475713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016475713&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.03.006

DO - 10.1016/j.lungcan.2017.03.006

M3 - Article

C2 - 28625622

AN - SCOPUS:85016475713

VL - 108

SP - 115

EP - 120

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -